Mission Statement

Santaris Pharma A/S, a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, is delivering on the promise of RNA medicines, today. The Company's proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine delivers potent single-stranded LNA-based drug candidates across a multitude of disease states.

Santaris Pharma A/S internal research and development activities currently focus on infectious diseases and metabolic disorders while partnerships with major pharmaceutical companies cover a range of therapeutic areas including cancer, infectious and inflammatory diseases and rare genetic disorders.

Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the US. As part of a broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNA-based drugs. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Pfizer and Shire plc.

Group Annual Report

The Group Annual Report 2009 includes the consolidated group financial statements prepared as the consolidated financial statements of the Danish parent company Santaris Pharma A/S, the US subsidiary Santaris Pharma A/S Corp. and the Danish subsidiary Stella ApS. In the Group Annual Report "Santaris Pharma A/S" or the "Company" means the "Santaris Pharma A/S Group" and includes the parent company and the subsidiaries.

The Group Annual Report 2009 is - pursuant to section 149 of the Danish Financial Statements Act - an extract of the parent company's Annual Report and does not include the financial statements of the parent company. The Annual Report for the parent company is available at the Company and has been filed with the Danish Commerce and Companies Agency.

CEO Review

Delivering on the promise of RNA medicines, today

Despite the turbulence in the global economy, 2009 was a highly successful year for Santaris Pharma A/S by numerous measures. We achieved several key clinical milestones through our internal and partner drugs in development, signed new business partnership agreements, expanded our operations by establishing operations in the United States, hired additional members to the executive management team and continued to position our business for sustainable growth through 2010 and beyond.